Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, John C. Byrd, Ross L. Levine et al.|Nature Medicine|2020Cited by 195
Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromeGeoffrey L. Uy, John F. DiPersio, Carmen Ballesteros‐Merino et al.|Blood|2017Cited by 62
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S. Advani, Wendy Stock, Eric Larsen et al.|Blood Advances|2021Cited by 53
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)Anjali S. Advani, Wendy Stock, Ben L. Sanford et al.|Blood|2013Cited by 47
Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Geoffrey L. Uy, John F. DiPersio, Michael P. Rettig et al.|Blood|2018Cited by 40